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Background
Mucosal immunity is critical in AIDS virus infection
because most transmission is through mucosal surfaces
and the GI mucosa is a major reservoir for virus replica-
tion. There is window in time in which mucosal T cells
could potentially eradicate a nascent local mucosal infec-
tion before it disseminates. In most vaccine work, adju-
vant-induced innate immunity was of interest only to
improve adaptive immunity. Here, in addition to adaptive
immunity, we also examine direct adjuvant effects on
innate immune protection.
Methods
We compared mucosal vaccine strategies involving syner-
gistic TLR ligands, IL-15, both or neither as adjuvants with
peptide-prime/MVA boost intrarectal vaccine, and have
searched for possible correlates of protection against
mucosal challenge.
Results
Only the group receiving all the adjuvants together with
vaccine antigens achieved at least partial protection of rhe-
sus macaques against intrarectal SIVmac251 challenge in
3 of 5 macaques. The optimal combination of several TLR
ligands and IL-15 induced not only a more effective adap-
tive T cell response, but also an innate immune response
that directly impacted protection. In the innate response,
we found evidence for vaccine-induced long-lasting
upregulation of APOBEC3G that provided some protec-
tion even in control animals that received only the adju-
vants without the vaccine antigens. In the adaptive
response, only polyfunctional CD8 T cells correlated with
protection, whereas levels of tetramer-positive cells and
even effector and central memory T cells surprisingly did
not.
Conclusion
Thus, strategic use of combinations of molecular adju-
vants can provide better mucosal protection through
induction of both innate and adaptive immunity.
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